Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 94 clinical trials
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in

  • 32 views
  • 29 Apr, 2021
  • 149 locations
featured
  • 251 views
  • 29 Apr, 2021
  • 135 locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, as compared to best available therapy, for adult participants with MF.

  • 164 views
  • 29 Apr, 2021
  • 225 locations
featured
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.  

leukemia
myeloproliferative disorders
myelofibrosis
  • 141 views
  • 14 Dec, 2020
  • 11 locations
featured
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period

eczema
atopic dermatitis
atopic dermatitis/eczema
  • 242 views
  • 14 Dec, 2020
  • 38 locations
featured
INCB 18424-304: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE-AD2) for 304

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period

dermatitis
eczema
atopic dermatitis
atopic dermatitis/eczema
  • 379 views
  • 14 Dec, 2020
  • 23 locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

myeloproliferative/myelodysplastic disorders
myeloproliferative disorder
myeloproliferative syndromes
myelofibrosis
myeloproliferative disorders
  • 0 views
  • 22 Jan, 2021
  • 1 location
featured
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

stem cell transplantation
bone marrow transplant
nutritional supplement
stem cell transplant
transplant conditioning
  • 300 views
  • 08 Dec, 2020
  • 1 location
featured
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally at a starting dose of 50 mg QD in

anemia
  • 67 views
  • 05 Oct, 2020
  • 1 location
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a

hydroxyurea
interferon
ruxolitinib
  • 0 views
  • 24 Jan, 2021
  • 2 locations